
Ann-Kathrin Lehnhausen

Studies on Competition and Antitrust Issues in the Pharmaceutical Industry

With a preface by Dr. Johannes Paha



Springer Gabler

Table of Content

Table of Figures.....	XI
Table of Abbreviations	XIII
1. Introduction	1
2. The Pharmaceutical Industry	5
2.1 Facts and Figures	5
2.2 R&D Process and Cost Development	6
2.3 Pharmaceutical Supply Chain	11
2.4 Different Regulatory Provisions	16
2.5 Overview of Antitrust and Competition Issues in the Pharmaceutical Industry	17
3. Anticompetitive actions taken by one firm only	23
3.1 Vertical Restraints under Parallel Trade	23
3.1.1 Vertical Integration.....	26
3.1.2 Price Discrimination.....	30
3.1.3 Resale Price Maintenance.....	32
3.1.4 Product Change	35
3.1.5 Dual Pricing.....	37
3.2 Competitive Restraints under Reference Pricing	38
3.3 Restraints against Generic Entry	43
3.3.1 Branded Generics	43
3.1.4 Product Hopping.....	48
3.1.5 Extending Indication Approval	52
4. Interactions Between Two or More Firms	59
4.1 Pay for Delay.....	59
4.2 Merger and Acquisition	64
5. Conclusion	69
Bibliography	71
Online References.....	83